TY - JOUR
T1 - Cerebrospinal fluid, plasma, and saliva in the BioFIND study
T2 - Relationships among biomarkers and Parkinson's disease Features
AU - The Fox Investigation of New Biomarker Discovery
AU - Goldman, Jennifer G
AU - Andrews, Howard
AU - Amara, Amy
AU - Naito, Anna
AU - Alcalay, Roy N.
AU - Shaw, Leslie M.
AU - Taylor, Peggy
AU - Xie, Tao
AU - Tuite, Paul
AU - Henchcliffe, Claire
AU - Hogarth, Penelope
AU - Frank, Samuel
AU - Saint-Hilaire, Marie Helene
AU - Frasier, Mark
AU - Arnedo, Vanessa
AU - Reimer, Alyssa N.
AU - Sutherland, Margaret
AU - Swanson-Fischer, Christine
AU - Gwinn, Katrina
AU - Kang, Un Jung
N1 - Funding Information:
*Corresponding author: Dr. Jennifer G. Goldman, Rush University Medical Center, 1725 W. Harrison Street, Suite 755, Chicago, IL 60612; Jennifer_G_Goldman@rush.edu Funding agencies: BioFIND is sponsored by The Michael J. Fox Foundation for Parkinson’s Research with support from the National Institute for Neurological Disorders and Stroke.
Publisher Copyright:
© 2017 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.
PY - 2018/2
Y1 - 2018/2
N2 - Objective: Examine relationships among neurodegenerative biomarkers and PD motor and nonmotor symptoms. Background: CSF alpha-synuclein is decreased in PD versus healthy controls, but whether plasma and saliva alpha-synuclein differentiate these groups is controversial. Correlations of alpha-synuclein among biofluids (CSF, plasma, saliva) or biomarkers (eg, beta-amyloid, tau [total, phosphorylated]) are not fully understood. The relationships of these biomarkers with PD clinical features remain unclear. Methods: BioFIND, a cross-sectional, observational study, examines clinical and biomarker characteristics in moderate-advanced PD and matched healthy controls. We compared alpha-synuclein concentrations across diagnosis, biofluids, and CSF biomarkers. Correlations of CSF biomarkers and MDS-UPDRS, motor phenotype, MoCA, and rapid eye movement sleep behavior disorder questionnaire scores in PD were examined. Results: CSF alpha-synuclein was lower in PD versus controls (P =.01), controlling for age, gender, and education. Plasma and saliva alpha-synuclein did not differ between PD and controls, and alpha-synuclein did not significantly correlate among biofluids. CSF beta-amyloid1-42 was lower in PD versus controls (P <.01), and correlated weakly with MoCA recall scores (r = 0.23, P =.02). CSF alpha-synuclein was lower in the postural instability/gait difficulty phenotype than other motor phenotypes (P <.01). No CSF biomarkers predicted or correlated with total motor or rapid eye movement sleep behavior disorder scores. CSF alpha-synuclein correlated with beta-amyloid1-42, total-tau, and phosphorylated-tau (r = 0.41, 0.81, 0.43, respectively; Ps <.001). Conclusion: Lower CSF alpha-synuclein is associated with diagnosis and motor phenotype in moderate-advanced PD. Plasma and saliva alpha-synuclein neither correlate with CSF alpha-synuclein, nor distinguish PD from controls. CSF beta-amyloid1-42 remains a potential biomarker for cognitive impairment in PD.
AB - Objective: Examine relationships among neurodegenerative biomarkers and PD motor and nonmotor symptoms. Background: CSF alpha-synuclein is decreased in PD versus healthy controls, but whether plasma and saliva alpha-synuclein differentiate these groups is controversial. Correlations of alpha-synuclein among biofluids (CSF, plasma, saliva) or biomarkers (eg, beta-amyloid, tau [total, phosphorylated]) are not fully understood. The relationships of these biomarkers with PD clinical features remain unclear. Methods: BioFIND, a cross-sectional, observational study, examines clinical and biomarker characteristics in moderate-advanced PD and matched healthy controls. We compared alpha-synuclein concentrations across diagnosis, biofluids, and CSF biomarkers. Correlations of CSF biomarkers and MDS-UPDRS, motor phenotype, MoCA, and rapid eye movement sleep behavior disorder questionnaire scores in PD were examined. Results: CSF alpha-synuclein was lower in PD versus controls (P =.01), controlling for age, gender, and education. Plasma and saliva alpha-synuclein did not differ between PD and controls, and alpha-synuclein did not significantly correlate among biofluids. CSF beta-amyloid1-42 was lower in PD versus controls (P <.01), and correlated weakly with MoCA recall scores (r = 0.23, P =.02). CSF alpha-synuclein was lower in the postural instability/gait difficulty phenotype than other motor phenotypes (P <.01). No CSF biomarkers predicted or correlated with total motor or rapid eye movement sleep behavior disorder scores. CSF alpha-synuclein correlated with beta-amyloid1-42, total-tau, and phosphorylated-tau (r = 0.41, 0.81, 0.43, respectively; Ps <.001). Conclusion: Lower CSF alpha-synuclein is associated with diagnosis and motor phenotype in moderate-advanced PD. Plasma and saliva alpha-synuclein neither correlate with CSF alpha-synuclein, nor distinguish PD from controls. CSF beta-amyloid1-42 remains a potential biomarker for cognitive impairment in PD.
KW - alpha-synuclein
KW - amyloid
KW - cerebrospinal fluid
KW - postural instability gait difficulty
KW - tau
UR - http://www.scopus.com/inward/record.url?scp=85038265593&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85038265593&partnerID=8YFLogxK
U2 - 10.1002/mds.27232
DO - 10.1002/mds.27232
M3 - Article
C2 - 29205509
AN - SCOPUS:85038265593
SN - 0885-3185
VL - 33
SP - 282
EP - 288
JO - Movement Disorders
JF - Movement Disorders
IS - 2
ER -